Elevated triglycerides are associated with decreased executive function among adolescents with bipolar disorder

Acta Psychiatrica Scandinavica

Volumn 134, Issue 3, 2016, Pages 241-248

  Naiberg, M R ^a,b   Newton, D F ^a,b   Collins, J E ^a   Dickstein, D P ^c   Bowie, C R ^d,e   Goldstein, B I ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c E P BRADLEY HOSPITAL   (United States)

^d QUEEN S UNIVERSITY   (Canada)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

bipolar disorder; cognition; lipid; metabolic syndrome; neurocognition

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; COGNITION ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EXECUTIVE FUNCTION; FEMALE; HUMAN; INTELLIGENCE QUOTIENT; MALE; METABOLIC SYNDROME X; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84981293996     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12603     Document Type: Article

References (57)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–1442.
2. Kessler RC, Avenevoli S, Green J et al. National comorbidity survey replication adolescent supplement (NCS-A): III. Concordance of DSM-IV/CIDI diagnoses with clinical reassessments. J Am Acad Child Adolesc Psychiatry 2009;48:386–399.
3. Goldstein BI, Herrmann N, Shulman KI. Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample. Am J Psychiatry 2006;163:319–321.
4. Dickstein DP, Nelson EE, Mcclure EB et al. Cognitive flexibility in phenotypes of pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007;46:341–355.
5. Burdick KE, Braga RJ, Goldberg JF, Malhotra AK. Cognitive dysfunction in bipolar disorder. CNS Drugs 2007;21:971–981.
6. Depp CA, Mausbach BT, Harmell AL et al. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord 2012;14:217–226.
7. Westman J, Hällgren J, Wahlbeck K, Erlinge D, Alfredsson L, Ösby U. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open 2013;3:e002373.
8. Goldstein BI, Carnethon MR, Matthews KA et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease a scientific statement from the American Heart Association. Circulation 2015;132:965–986.
9. Sharma R, Markar H. Mortality in affective disorder. J Affect Disord 1994;31:91–96.
10. Goldstein BI, Birmaher B, Axelson DA et al. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry 2008;69:1953.
11. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004;109:433–438.
12. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008;20:131–137.
13. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005;7:424–430.
14. Jerrell JM, Mcintyre RS, Tripathi A. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry 2010;71:1478–1525.
15. Martino F, Puddu PE, Pannarale G et al. Metabolic syndrome among children and adolescents from Southern Italy: Contribution from the Calabrian Sierras Community Study (CSCS). Int J Cardiol 2014;177:455–460.
16. Salvi V, D'Ambrosio V, Rosso G, Bogetto F, Maina G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci 2011;65:47–54.
17. Robinson LJ, Thompson JM, Gallagher P et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006;93:105–115.
18. Elias M, Elias P, Sullivan L, Wolf P, D'Agostino R. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obesity 2003;27:260–268.
19. Reynolds CA, Gatz M, Prince JA, Berg S, Pedersen NL. Serum lipid levels and cognitive change in late life. J Am Geriatr Soc 2010;58:501–509.
20. Sheline YI, Barch DM, Garcia K et al. Cognitive function in late life depression: relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry 2006;60:58–65.
21. Yim C, Soczynska J, Kennedy S, Woldeyohannes H, Brietzke E, Mcintyre R. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry 2012;27:223–228.
22. Birmaher B, Axelson D, Strober M et al. Clinical course of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006;63:175–183.
23. Kaufman J, Birmaher B, Brent D et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980–988.
24. Weissman MM, Wickramaratne P, Adams P, Wolk S, Verdeli H, Olfson M. Brief screening for family psychiatric history: the family history screen. Arch Gen Psychiatry 2000;57:675–682.
25. Axelson D, Birmaher BJ, Brent D et al. A preliminary study of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children mania rating scale for children and adolescents. J Child Adolesc Psychopharmacol 2003;13:463–470.
26. Chambers WJ, Puig-Antich J, Hirsch M et al. The assessment of affective disorders in children and adolescents by semistructured interview: test-retest reliability of the Schedule for Affective Disorders and Schizophrenia for School-Age Children, Present Episode Version. Arch Gen Psychiatry 1985;42:696–702.
27. Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D. Assessment of child and adolescent overweight and obesity. Pediatrics 2007;120:S193–S228.
28. Zimmet P, Alberti KGM, Kaufman F et al. The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabet 2007;8:299–306.
29. Wechsler D. Wechsler abbreviated scale of intelligence. San Antonio, TX: Psychological Corporation, 1999.
30. Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002;2:1.
31. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007;46:687–700.
32. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765–1773.
33. Mcintyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 2008;162:929–935.
34. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol) 1995;57:289–300.
35. Bowie CR, Depp C, Mcgrath JA et al. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am J Psychiatry 2010;167:1116–1124.
36. Segura B, Jurado MÁ, Freixenet N, Albuin C, Muniesa J, Junqué C. Mental slowness and executive dysfunctions in patients with metabolic syndrome. Neurosci Lett 2009;462:49–53.
37. Yau PL, Kang EH, Javier DC, Convit A. Preliminary evidence of cognitive and brain abnormalities in uncomplicated adolescent obesity. Obesity 2014;22:1865–1871.
38. van Dijk EJ, Breteler MM, Schmidt R et al. The association between blood pressure, hypertension, and cerebral white matter lesions cardiovascular determinants of dementia study. Hypertension 2004;44:625–630.
39. Pa J, Boxer A, Chao LL et al. Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol 2009;65:414–423.
40. Iso H, Imano H, Yamagishi K et al. Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis 2014;237:361–368.
41. Bowman TS, Sesso HD, Ma J et al. Cholesterol and the risk of ischemic stroke. Stroke 2003;34:2930–2934.
42. Shahar E, Chambless LE, Rosamond WD et al. Plasma lipid profile and incident ischemic stroke the Atherosclerosis Risk in communities (ARIC) study. Stroke 2003;34:623–631.
43. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999;83:25–29.
44. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005;17:83–93.
45. Abbatecola AM, Paolisso G, Lamponi M et al. Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 2004;52:1713–1718.
46. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2012;9:35.
47. Moreira PI, Santos MS, Seiça R, Oliveira CR. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 2007;257:206–214.
48. Serlin Y, Levy J, Shalev H. Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol 2011;2011:1–10. DOI: 10.1155/2011/609202
49. Singh DK, Winocour P, Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 2011;7:176–184.
50. Starr J, Wardlaw J, Ferguson K, Maclullich A, Deary I, Marshall I. Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003;74:70–76.
51. Mcintyre RS, Soczynska JK, Woldeyohannes HO et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord 2012;14:697–706.
52. Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology and pathophysiology—emerging clinical applications. Nat Clin Pract Endocrinol Metab 2006;2:318–327.
53. Banks WA, Coon AB, Robinson SM et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004;53:1253–1260.
54. Farr OM, Tsoukas MA, Mantzoros CS. Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders. Metabolism 2015;64:114–130.
55. Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, Yaffe K. Serum leptin level and cognition in the elderly: findings from the Health ABC Study. Neurobiol Aging 2009;30:1483–1489.
56. Paz-Filho GJ, Babikian T, Asarnow R et al. Leptin replacement improves cognitive development. PLoS ONE 2008;3:e3098.
57. Smith E, Hay P, Campbell L, Trollor J. A review of the association between obesity and cognitive function across the lifespan: implications for novel approaches to prevention and treatment. Obes Rev 2011;12:740–755.